ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Mohamed Zaid
Matched on ORCID iD 0000-0002-8615-2456; OpenAlex author ID A5046059508. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 72
2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers
Papers 11
- Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.04.044↗
- Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… First author DOI 10.1016/j.ijrobp.2022.06.089↗
- Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.12.273↗
- Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2020.11.003↗
- Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
- Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Co-author DOI 10.3390/cancers12123656↗
- Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
- Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer. Co-author DOI 10.15252/emmm.201910515↗
- Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… First author DOI 10.1002/cncr.31251↗
- A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
- Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.06.026↗
Closest collaborators
The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Eugene Jon Koay · 10 shared papers, 2017–2022 · strength 0.82
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Anirban Maitra · 8 shared papers, 2018–2022 · strength 0.70
- Paper Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocar… DOI 10.1053/j.gastro.2021.12.273↗
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Matthew H. G. Katz · 7 shared papers, 2018–2022 · strength 0.60
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Huamin Wang · 7 shared papers, 2018–2022 · strength 0.60
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Robert A. Wolff · 7 shared papers, 2018–2022 · strength 0.60
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Eric Peter Tamm · 7 shared papers, 2018–2022 · strength 0.56
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC)… DOI 10.3390/cancers12123656↗
- Priya Bhosale · 6 shared papers, 2018–2022 · strength 0.48
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC)… DOI 10.3390/cancers12123656↗
- Gauri Rajani Varadhachary · 6 shared papers, 2018–2022 · strength 0.48
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC)… DOI 10.3390/cancers12123656↗
- Christopher H. Crane · 5 shared papers, 2018–2022 · strength 0.40
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for B… DOI 10.1200/po.19.00001↗
- Jeffrey E. Lee · 5 shared papers, 2018–2022 · strength 0.39
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for B… DOI 10.1200/po.19.00001↗
- Cullen M. Taniguchi · 4 shared papers, 2018–2022 · strength 0.33
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography sca… DOI 10.1002/cncr.31251↗
- Joseph M. Herman · 3 shared papers, 2018–2022 · strength 0.26
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC)… DOI 10.3390/cancers12123656↗
- Paper Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography sca… DOI 10.1002/cncr.31251↗
- Michael P. Kim · 3 shared papers, 2018–2022 · strength 0.26
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarci… DOI 10.1158/1078-0432.ccr-17-3668↗
- Yeon‐Ju Lee · 4 shared papers, 2017–2019 · strength 0.24
- Paper Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for B… DOI 10.1200/po.19.00001↗
- Paper Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal ad… DOI 10.1016/j.canlet.2017.06.026↗
- Paper Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography sca… DOI 10.1002/cncr.31251↗
- Sunil Krishnan Krishnan · 3 shared papers, 2018–2022 · strength 0.23
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for B… DOI 10.1200/po.19.00001↗
- Paper Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography sca… DOI 10.1002/cncr.31251↗
- Milind M. Javle · 3 shared papers, 2018–2022 · strength 0.23
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for B… DOI 10.1200/po.19.00001↗
- Paper A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarci… DOI 10.1158/1078-0432.ccr-17-3668↗
- Albert C. Koong · 2 shared papers, 2022 · strength 0.22
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Grace L. Smith · 2 shared papers, 2022 · strength 0.22
- Paper Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. DOI 10.1016/j.ijrobp.2022.04.044↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Ching-Wei David Tzeng · 2 shared papers, 2021–2022 · strength 0.21
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Aatur Dilip Singhi · 2 shared papers, 2020–2022 · strength 0.21
- Paper Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocar… DOI 10.1053/j.gastro.2021.12.273↗
- Paper Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pr… DOI 10.3389/fonc.2020.596931↗
- Abdel Nasser Hosein · 2 shared papers, 2019–2022 · strength 0.21
- Jason B. Fleming · 3 shared papers, 2018–2019 · strength 0.18
- Paper Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for B… DOI 10.1200/po.19.00001↗
- Paper Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography sca… DOI 10.1002/cncr.31251↗
- Paper A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarci… DOI 10.1158/1078-0432.ccr-17-3668↗
- Laura R. Prakash · 2 shared papers, 2019–2021 · strength 0.18
- Paper Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic du… DOI 10.1016/j.pan.2020.11.003↗
- Paper Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for B… DOI 10.1200/po.19.00001↗
- Michael James Overman · 2 shared papers, 2018–2022 · strength 0.16
- Paper Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Adva… DOI 10.1016/j.ijrobp.2022.06.089↗
- Paper Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography sca… DOI 10.1002/cncr.31251↗
- Takashi Okumura · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.